Citations

Clear

4206 citation(s) found for "Chen, Yu".

Novel transplantable mouse cell line model recapitulates invasive lobular breast carcinoma (ILC) phenotype and immune microenvironment
Onkar, Sayali , Liu, Daisong, Seachrist, Darcie D. , Zou, Jian , Merkel, Christopher , Thale, Insa , Chang, Alexander Chih-Chieh , Klei, Linda R. , Chen, Jian, Weber-Bonk, Kristen L. , Rigatti, Laura, Workman, Creg J. , Oesterreich, Steffi , Seachrist, Darcie , Klei, Linda , Bonk, Kristen Weber , Ding, Kai , Savariau, Laura , Yates, Megan , Hooda, Jagmohan , Stabile, Laura , Lucas, Peter C , Ruth, Keri , Workman, Creg J , Lee, Adrian V , Vignali, Dario A A , Oesterreich, Steffi , Savariau, Laura , Lucas, Peter C. , Tseng, George , Lee, Adrian V.

Mayo Clinic

No container title available | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.30.741815 | PMID 42620030 Get It

Abstract Invasive lobular breast carcinoma (ILC) is the most common special histological subtype of breast cancer, which accounts for 10-15% of all cases. To study the phenotype characteristics, metastatic growth kinetic and immune microenvironment of ILC, we developed an orthotopically transplantable cell line model from the spontaneous mammary fat pad tumor of CDH1-PTEN dual knockout C57BL/6 mouse with Cre-loxP system, designated CPT6. CPT6 recapitulates single-file growth pattern of human ILC, with pleomorphic features and a high mitotic index. RNA sequencing together with whole exome sequencing reveals a luminal A subtype with targetable driver mutations such as Kras G12C. As a novel orthotopically transplantable ILC model in immune competent mice, CPT6 shows robust in vivo growth and metastatic rate, and has moderate immunogenicity which appears to be T-cell independent. We also profiled the immune microenvironment of CPT6, revealing a myeloid-rich environment with dominant M2-macrophage population, which is concordant with human ILC. In summary, this model recapitulates human ILC phenotype and represents a valuable preclinical platform for evaluating immunotherapy and other therapeutic strategies for invasive lobular breast carcinoma.
Cross-Validation of Low-Cost Potentiometric and Colorimetric Methods for Urinary Urea Quantification: Toward Accessible Monitoring of Protein Metabolism
Domínguez, R. , Yang, Valerie, Fu, Ashley, Cheng, Edward H., Terrera, Mirna, Hota, Piyush , Pradhan, Ayushi, Miranda, Sandra, Snozek, Christine, Thomas, Leslie, Lind, Mary Laura , Chen, Fang, Forzani, Erica, Dominguez, Rodrigo E , Cheng, Edward H., Miranda, Sandra, Thomas, Leslie F. , Forzani, Erica

Mayo Clinic

Analytica | July 31, 2026 | Volume: 7 | Issue: 3 | Pages: 51

10.3390/analytica7030051 Get It

Urinary urea is a key biomarker for tracking protein oxidation and nitrogen balance. A persistent analytical limitation is that conventional total-nitrogen assays do not deconvolute urinary urea from urinary ammonia, and direct measurement still requires capital-intensive clinical analyzers. Here, we implement and independently validate two cost-effective methods that resolve urinary urea by pairing the presence and absence of urease: Method 1 is a urease-coupled potentiometric assay using an ammonium ion-selective electrode (ISE method); Method 2 is a microplate Berthelot–salicylate colorimetric assay employing a repurposed consumer-grade aquarium ammonia test kit (API®) (API method). Each method was validated against the Roche Cobas C311 clinical analyzer (ISE for urinary ammonia and API for urinary urea) in healthy adult volunteers (n = 10 each), and API–ISE were then compared head-to-head for urinary urea. ISE vs. Cobas yielded R2 = 0.967, slope 95% CI [0.867, 1.173], and Bland–Altman bias of −1.02 mM (95% LoA [−7.40, +5.36] mM). API vs. Cobas yielded R2 = 0.973, slope 95% CI [0.790, 1.039], and bias of −1.55 mM (95% LoA [−11.56, +8.46] mM). API–ISE urinary urea comparison confirmed mutual agreement (R2 = 0.9976, slope 95% CI [0.946, 1.024]; bias of +3.47 mM; 95% LoA [−14.60, +21.53] mM), with mean recoveries near 100% (API: 100.7 ± 2.9%; ISE: 100.6 ± 5.4%; 20–350 mM). Both methods agreed with the clinical analyzer, supporting their potential for decentralized, resource-limited testing; clinical and point-of-care validations are needed.
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML
Levis, Mark J. , Hamadani, Mehdi , Logan, Brent R, Jones, Richard J., Singh, Anurag K, Litzow, Mark R. , Papadopoulos, Esperanza B. , Perl, Alexander E. , Soiffer, Robert J., Üstün, Celalettin , Vasu, Sumithira, Solh, Melhem , Mishra, Asmita , Muffly, Lori , Stelljes, Matthias, Onozawa, Masahiro , Thomson, Kirsty , Chen, Caroline , Hasabou, Nahla, Rosales, Matt, Gill, Stanley C. , Nuthethi, Rishita, King, Denise , Mendizabal, Adam , Horowitz, Mary M, Chen, Yi‐Bin , Papadopoulos, Esperanza , Perl, Alexander E , Ustun, Celalettin , Ueda Oshima, Masumi , Uy, Geoffrey , Waller, Edmund K , Muffly, Lori , Kim, Hee-Je , Najima, Yuho , Onozawa, Masahiro , Hill, Jason , Devine, Steven , Chen, Yi-Bin , Hamadani, Mehdi , Logan, Brent R. , Jones, Richard J. , Singh, Anurag K. , Wingard, John R. , Soiffer, Robert J. , Ueda, Masumi , Uy, Geoffrey L. , Waller, Edmund K. , Vasu, Sumithira , Stelljes, Matthias , Hill, Jason E. , Devine, Steven M. , Horowitz, Mary M.

Mayo Clinic

Blood Advances | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020327 | PMID 42532509 Get It

BMT CTN 1506 ("MORPHO") was a phase 3 study of post-hematopoietic cell transplantation (HCT) maintenance with gilteritinib versus placebo for patients with FLT3-ITD-mutated acute myeloid leukemia (AML) in first remission. Subgroup analysis indicated a significant benefit of post-HCT gilteritinib for participants in North America, but no benefit for those in Europe or Asia. We conducted a post-hoc analysis of the data focusing on days from AML diagnosis to HCT, pre-HCT FLT3 inhibitor use, and FLT3-ITD measurable residual disease (MRD). Participants transplanted < 120 days from AML diagnosis and/or those treated with FLT3 inhibition pre-HCT were more likely to have improved survival from post-HCT gilteritinib. Pre-HCT MRD levels were higher (P = 0.001) in participants transplanted within 120 days from diagnosis and in those treated with a FLT3 inhibitor pre-HCT and transplanted within 120 days (P = 0.008). Pre-HCT MRD was dependent on both FLT3 inhibitor use and time to HCT, as participants treated with successive courses of chemotherapy + FLT3 inhibition had successively lower MRD by the time of HCT. Time from AML diagnosis to HCT and pre-HCT FLT3 inhibitor use both appeared to impact MRD levels immediately prior to HCT, and geographic differences in these two practice patterns likely accounted for the observed regional differences in benefit from post-HCT gilteritinib. Increasing the number of courses of treatment pre-HCT may lower MRD sufficiently to eliminate the need for post-HCT inhibition, but with a presumed risk of some patients experiencing early progression. This trial was registered at www.clinicaltrials.gov as #NCT02997202.
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2 -Negative Breast Cancer
Isaacs, Claudine, Nanda, Rita, Yau, C, Chien, A. Jo, Hershman, Dawn L., Stringer-Reasor, Erica M., Wallace, Anne M., Clark, Amy S., Kennedy, Laura C., Sanford, Amy, Boughey, JC , Albain, Kathy S. , Pusztai, Lajos, Kalinsky, Kevin M., Beckwith, Heather, Williams, Nicole O., Han, Hyo S., Falkson, Carla, Arora, Mili, Pohlmann, Paula R., Rozenblit, Mariya, Marshall, Natalie, Chen, Yunn-Yi, McGuinness, Julia E., Howard, Frederick M., Chen, Nan, Khoury, Katia, Lancaster, Rachael, Douglas, Emily, Wei, Mei, Mainor, Candace, LeStage, Barbara, Matthews, Jeffrey B. , Perlmutter, J, Symmans, W. Fraser, Yee, Douglas, Hylton, Nola M., Veer, Laura van ‘t , Rugo, Hope S., Berry, Donald A., Esserman, Laura J., Isaacs, Claudine , Yau, Christina , Chien, A. Jo , Hershman, Dawn L. , Stringer-Reasor, Erica , Thomas, Alexandra , Vaklavas, Christos , Clark, Amy S. , Kennedy, Laura Carpin , Pusztai, Lajos , Kalinsky, Kevin M. , Beckwith, Heather , Han, Hyo S , Falkson, Carla I. , Arora, Mili, Elias, Anthony , Pohlmann, Paula R. , Rozenblit, Mariya , Trivedi, Meghna S. , McGuinness, Julia Elizabeth , Howard, F , Khoury, Katia , Yeung, Kay T. , Douglas, Emily, Mainor, Candace , LeStage, Barbara , Delson, Amy , Asare, Adam L. , Swigart, Lamorna Brown , Hirst, Gillian L. , Symmans, W. Fraser , Yee, Douglas , Veer, Laura J. van’t , Rugo, Hope S. , DeMichele, Angela , Berry, Donald A., Esserman, Laura J.

Mayo Clinic

JAMA Oncology | July 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaoncol.2026.2576 | PMID 42530945 Get It

Importance Although adding immune checkpoint inhibitors to neoadjuvant chemotherapy improves outcomes in high-risk early-stage breast cancer, opportunities remain to further enhance response. Dual checkpoint blockade offers a potential strategy to further enhance efficacy. Objective To evaluate the combination of anti−programmed cell death 1 protein (PD-1) cemiplimab and anti−lymphocyte activation gene 3 (LAG-3) added to neoadjuvant therapy in ERBB2 -negative early-stage, high-risk breast cancer. Design, Setting, and Participants The I-SPY2 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis 2) is an ongoing randomized clinical platform trial being conducted at multiple US clinical sites including patients with early-stage (II or III) ERBB2 -negative, high-risk breast cancer. Participants, continuously enrolled since 2010, were adaptively randomized from February 2, 2020, to December 9, 2021, to one of several experimental neoadjuvant therapies or control groups based on receptor subtypes defined by hormone receptor (HR), ERBB2 status, and MammaPrint (Agendia Inc) molecular risk, categorized as high (MP1) or ultrahigh (MP2). Data were analyzed from January 1, 2022, to August 5, 2025. Interventions Both groups received weekly paclitaxel for 12 weeks, then doxorubicin and cyclophosphamide followed by surgery; concomitant with paclitaxel, the intervention group also received 4 doses of cemiplimab and fianlimab (PCF) every 3 weeks. Main Outcomes and Measures Pathologic complete response (pCR). Treatments graduated when they achieved 85% bayesian probability of success in a subtype-specific phase 3 trial. Pathway-specific biomarkers were assessed for response prediction. Results A total of 78 participants (mean [SD] age, 47 [39-54] years) were randomized to the intervention group, with 350 participants (mean [SD] age, 48 [39-57] years) randomized to the historical control population. PCF graduated in all clinical signatures, with pCR rates vs control of 44% (95% CI, 34%-53%) vs 21% (95% CI, 17%-25%) in all ERBB2 , 53% (95% CI, 39%-67%) vs 29% (95% CI, 22%-36%) in triple-negative, and 36% (95% CI, 23%-49%) vs 14% (95% CI, 9%-19%) in HR-positive and ERBB2 -negative disease. Among the total participants, 16 (21%) experienced adrenal insufficiency, including hypophysitis (11% grade 3 or 4), mostly occurring after immunotherapy completion. PCF was found to be highly effective in the subset of patients with immune signature positive status (ImPrint positive). Conclusions and Relevance In this randomized clinical trial, the combination of PD-1 and anti−LAG-3 inhibition with standard NAC was effective in early-stage ERBB2 -negative breast cancer, particularly in patients displaying a positive ImPrint immune signature. These results warrant further definitive trials. Trial Registration ClinicalTrials.gov Identifier: NCT01042379
Cardiovascular Health Across the Life Course for Individuals With Breast Cancer
Mauricio, Rina, Deswal, Anita, Ruddy, Kathryn J., Chen, Ming Hui, Ebong, Imo A., Aggarwal, Niti R., Harrington, Colleen , Barcenas, Carlos H., Mitchell, Melissa P. , Cho, Leslie , Nohria, Anju, Mauricio, Rina , Deswal, Anita M , Ruddy, Kathryn J. , Akhter, Nausheen , Ebong, Imo , Barcenas, Carlos Hernando , Nohria, Anju

Mayo Clinic

JAMA Cardiology | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamacardio.2026.2546 | PMID 42525430 Get It

Importance Breast cancer is the most common cancer diagnosed in women. Therapies for breast cancer are evolving rapidly, and several are associated with cardiovascular adverse effects, can exacerbate cardiovascular risk factors, or can increase the risk of cardiovascular disease. Observations Advances in screening and treatment have led to earlier diagnosis and improved disease-free survival. For long-term survivors of breast cancer, cardiovascular adverse effects can pose a greater threat to overall long-term health than the cancer itself. Additionally, the increasing incidence of breast cancer in younger, premenopausal women has created a distinct demographic with unique medical needs. Conclusions and Relevance Cardiology practitioners need to remain updated on rapidly evolving breast cancer therapies to care for this growing, unique patient population. The field of cardio-oncology has evolved to address the cardiovascular needs of patients and survivors.
Global Burden of Elevated LDL-C
Collaborators, GBD 2023 LDL Cholesterol, Razo, Christian, DeCleene, Nicole K., Johnson, Catherine O., Stark, Benjamin, LeGrand, Kate, Aalruz, Hasan, Abaraogu, Ukachukwu O., Abdelnabi, Mahmoud, Abd-Elsalam, Sherief, Abdelwahab, Siddig Ibrahim, Abdollahi, Arash, Abdrabou, Mostafa M., Abdul‐Rahman, Toufik , Getahun, Habtamu Abebe, Abiodun, Olumide, Abohashem, Shady, Abonie, Ulric Sena , Abourashed, Nagah M , Abramov, Dmitry, Abrar, Mohammed Mehdi, Farha, Rana Kamal Abu, Abubakar, Bilyaminu, Aburuz, Salahdein, Abushanab, Dina, Adams, Lisa C., Adamu, Nuhu Lawan Lawan, Adegbile, Oluwatobi E , Adegoke, Nurudeen A., Adekola, Saheed Ayodeji, Adeleke, Olumide Thomas , Adesina, Miracle Ayomikun, Afoakwah, Clifford, Afolabi, Aanuoluwapo Adeyimika, Afrashteh, Fatemeh , Afrifa-Yamoah, Ebenezer, Agyemang‐Duah, Williams , Ahmad, Suhaib, Ahmed, Asma , Ahmed, Gasha Salih, Ahmed, Luai A., Ahmed, Mehrunnisha Sharif, Ahmed, Meqdad Saleh , Ahmed, M. , Ahmed, Mushood, Ahmed, Syed Anees, Ahmed, Zohra, Aiyer, Aishwarya, Ajami, Marjan, Akalanka, Kasuni H.M. , Akhtar, Muhammad Nadeem, Akrami, Ashley E, Akyea, Ralph Kwame, Hasan, Syed Mahfuz Al , Zoubi, Mohammad Ahmmad Mahmoud Al, Alahdab, Fares , Al-Ahmad, Mohammad M. , Alajajian, Stephen , Alajlani, Muaaz , Alalwan, Tariq A., Al-Amri, Issa Sulaiman, Alanzi, Turki M., Alarifi, Abdullah, Al-Azzam, Sayer, Albashtawy, Mohammed, Al-Dewik, Nader, Algahtani, Fahad D., Algammal, Abdelazeem M, Alhalaiqa, Fadwa Naji, Ali, Mohammad Daud , Ali, Mohammed Usman, Ali, Rafat, Ali, Syed Shujait, AL-Iede, Montaha, Alipour, Morteza, Al-Jabi, Samah W., Alkhatib, Mayson H. , Allawi, Raad Hatim , Allemailem, Khaled S. , (6837737), Mohammed Z. Allouh, Almahmeed, Wael, Al-Marwani, Sabah , Almazan, Joseph Uy, Alnaeem, Mohmmad Minwer, Alotaibi, Haifa F. F., Alqahtani, Saleh A, Alqudah, Mohammad , Alqudimat, Mohammad R, Al-Qudimat, Ahmad Rajeh, Alrimawi, Intima , Alrousan, Sahel Majed, Alshahrani, Najim Z., Altaany, Zaid, Altaf, Awais, Althobiani, Malik A., Altwalbeh, Diala, Al-Worafi, Yaser Mohammed, Aly, Hany, Alzoubi, Karem H., Al-Zubairi, Adel S., Amafah, Joy, Mohammadi, Masoud Aman, Amini, Saeed, Amini-Salehi, Ehsan, Ananda, Roshan A., Ancuceanu, Robert, Anil, Abhishek, Anjana, Prapti, Anuoluwa, Boluwatife Stephen, Anvari, Saeid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Appati, Walter, Arafa, Elshaimaa A , Aravkin, Aleksandr Y. , Areda, Demelash, Aregawi, Brhane Berhe, Torre, Jorge Arias de la, Arruda, Gustavo Aires , Asghari-Jafarabadi, Mohammad , Ashraf, Saad , Asare, Bernard Yeboah‐Asiamah , Atac, Omer, Athari, Seyyed Shamsadin, Atorkey, Prince , Aurangzeb, Khursheed, Awan, Usman Ayub , Awol, Kemal Lemnuro Lemnuro, Ayala, Camila Ospina , Ayli, Berrak Itir, Azad, A.K.M., Azzam, Ahmed Y., Babiker, Rasha, Badar, Muhammad, Badran, Alaa Aboelnour, Baghlaf, Khlood K., Balabekova, Marina, Balakrishnan, Senthilkumar , Baltatu, Ovidiu Constantin , Banach, Maciej, Bashir, Muhammad Irfan , Bashir, Shahid, Bashiri, Azadeh, Bastan, Mohammad-Mahdi, Bayat, Mahdis , Behera, Surama Manjari , Belayneh, Melesse, Bello, Abdulrahman Babatunde , Belo, Luís, Bhaskar, Sonu, Bizzozero-Peroni, Bruno, Bogale, Sitotaw Kerie, Bolourinejad, Paria , Bonny, Aimé , Carvajal, Alejandro Botero, Bouaoud, Souad, Britton, Gabrielle, Bustanji, Yasser, Butt, Zahid A., Cao, Yu, Catapano, Alberico L., Cegolon, Luca, Cembranel, Francieli , Chadwick, Joshua , Chau, Lam Duc, Chaudhary, Anis Ahmad, Chen, An-Tian, Chen, Hana, Chen, Haowei , Cheng, Haojin, Cheung, Ka Ching , Chew, Nicholas WS, Chi, Gerald, Cho, William C. S., Chong, Bryan, Chopra, Deepti, Chopra, Shivani , Cicero, Arrigo Francesco Giuseppe, Criqui, Michael H., Cruz-Martins, Natalia, Dahabiyeh, Lina, Khatri, Bishal Dahal , Dalakoti, Mayank, D’Amico, Emanuele, Damtie, Endalamaw Tesfa, Dandona, Lalit , Dandona, Rakhi, D’Anna, Lucio , Danpanichkul, Pojsakorn, Dardas, Latefa Ali , Das, Sayan Kumar, Davletov, Dimash, Dergaa, Ismail, Derseh, Hunegnaw Almaw , Desale, Aragaw Tesfaw, Devanbu, Vinoth Gnana Chellaiyan, Devegowda, Devananda, Dewan, Syed Masudur Rahman, Dhali, Arkadeep , Dhungel, Bibha, Silva, Diana Dias da, Didehvar, Kimia, Ding, Xueting, Do, Thanh Chi, Do, Thao Huynh Phuong, Dohare, Sushil, Dong, Dachuan, D’Oria, Mario, Dorostkar, Fariba, Doshi, Ojas Prakashbhai, Dresse, Menayit Tamrat , Du, Mi, Ebraheim, Lamiaa Labieb Mahmoud, Edeh, Cynthia , Eftekhari, Behrad, Sedeh, Ashkan Eighaei , Ekholuenetale, Michael , Arab, Rabie Adel El , Eldaboush, Ahmed, El-Dahiyat, Faris , Elhoumed, Mohamed, Elmeligy, Omar Abdelsadek Abdou, Elmonem, Mohamed A., Elmoselhi, Adel B., Elnaem, Mohamed Hassan , Eltahawy, Abdelgawad Salah, Etaee, Farshid, Fakhradiyev, Ildar , Fakorede, Sodiq, Farasani, Abdullah , Fareed, Mohammad , Farhana, Aisha, Faris, MoezAlIslam Ezzat Mahmoud, Farsi, Farima , Fatima, Zareen, Fazylov, Timur, Fekadu, Ginenus , Ferreira, Nuno, Fischer, Florian, Fonzo, Marco , Gadanya, Muktar A., Galali, Yaseen, Ganesh, Balasubramanian , Gangachannaiah, Shivaprakash, Gao, Dingwei, Garcia-Azorin, David, Garg, Paarth, Gautam, Rupesh K., Gaye, Bamba , Gebresilassie, Mizan Habtemichael, Gete, Kalab Yigermal , Ghadirian, Fataneh, Ghaffari, Kazem , Ghamkhar, Arin, Gharaibeh, Lobna, Ghasemi, Mohammadreza, Ghimire, Sailaja, Gil, Artyom Urievich, Gilani, Syed Abdullah , Gohari, Kimiya, Gohil, Megha Nishith , Golechha, Mahaveer, Goleij, Pouya , Golmohammadi, Melika , Goyal, Aman, Grada, Ayman, Grover, Ashna , Gu, Long, Gufue, Zenawi Hagos , Guo, Zheng, Gupta, Sapna , Gurgoglione, Filippo Luca, Haghtalab, Arian, Nam, Nguyen Hai, Hailu, Kirubel Tesfaye , Halder, Pritam, Hamdy, Nadia M., Hamidi, Hossein , Hamidi, Samer, Hamoudi, Rifat, Harsini, Sara, Hasnain, Md Saquib , Hassan, Ikrama, Hassan, Nageeb, Hassan, Treska S , Ahmed, Omed Hassan , Hebert, Jeffrey J., Helmy, Yosra A. , Hiraike, Yuta, Holla, Ramesh, Hoseinzadeh, Mehdi, Hostiuc, Mihaela , Hostiuc, Sorin, Hotwani, Priya, Hu, Yifei, Huang, Junjie, Huang, Yu-Song, Hushmandi, Kiavash, Hussein, Dursa, Hussein, Mohammed Asif , Ibrahim, Ismail A., Ibrayeva, Anel, Ikiroma, Adalia , Ikram, Jibran, Ilic, Irena M., Imam, Mohammad Tarique , Imani, Masoud, Imodoye, Sikiru Opeyemi, Imoh, Lucius Chidiebere , Ionescu, Andreea Iuliana, Ionescu, Radu Tudor, Iqhrammullah, Muhammad, Ishaqui, Azfar Athar, Islek, Duygu , ISMAIL, NAHLAH ELKUDSSIAH, Ismoldayev, Yerlan, Iwagami, Masao , Iyer, Mahalaxmi, Izquierdo-Condoy, Juan S.S., Jafari-Khounigh, Ali , Jahanshahi, Ali, Jahrami, Haitham , Jakovljevic, Mihajlo, Jamal, Armaan, Jamali, Navid, Jamaluddin, Jazlan , Jamshidi, Masoud, Jansen, Robin , Jarrahi, Esmaeil , Javaid, Syed Sarmad , Jawaid, Talha, JEBASINGH, FELIX, Jemal, Mohammed, Ji, Zixiang , Jibat, Nathan T., Jin, Wenyi , Jokar, Mohammad, Joseph, Nitin, Raj, Jesu Vijay Sheldon Joseph Michael, Joshi, Krupal, Joshua, Charity Ehimwenma, Jung, Sang-Hyuk, K, Vaishali, Kadir, Dler Hussein , Kahe, Farima, Kalani, Rizwan, Kalra, Sanjay, Kamenova, Saltanat, Kamorudeen, Ramat T., Kamyshnyi, Oleksandr, Kansal, Subham, Kantar, Rami S., Kar, Debasish , Karakasis, Paschalis, Karimi, Aliasghar, Behnagh, Arman Karimi , Karun, Sadanand , Kazemian, Sina, Kesse-Guyot, Emmanuelle, Khaleel, Anas, Khalid, Nauman, Khalid, Sidra, Khalil, Anees Ahmed , Khan, Ajmal, Khan, Md Abdullah Saeed, Khan, Moien AB, Khan, Muhammad Hamza , Khan, Serab, Khan, Sumaiya, Khan, Yusuf S. , Kheirallah, Khalid A, Khoshvaght, Samira, Khosravi, Sepehr, Kim, Hye Jun, Kim, Kwanghyun, Kisa, Adnan, Kishore, Ladli, Kokkorakis, Michail, Kondybayeva, Aida, Krishan, Kewal, Kua, Chong-Han, Kuddus, Mohammed, Kulimbet, Mukhtar , Kulkarni, Vishnutheertha, Kumar, Dewesh , Kumar, Nitesh, Kumar, Sanjay Kirshan, Kunutsor, Setor K., Kurpad, Krishna Prasad , Kusuma, Dian, Lahariya, Chandrakant, Lai, Daphne Teck Ching , Lai, Hanpeng , Lajunen, Timo, Lakanova, Balzhan, Lallukka, Tea, Larsson, Anders O., Le, Duc Tin , Le, Thao T. , Le, Thoa, Le, Trang Thi Bich , Ledda, Caterina, Lee, Hayeon, Lee, Sang-woong, Lee, Sergey Vadimovich, Lee, Seung Won, Leivaditis, Vasileios, Lema, Gebretsadik Kiros , Lemma, Dawit Alemu, Lenjisa, Jimma, Lewis, Mitchelle Shilpa , Li, Chengfeng , Li, Xingang , Li, Yongze, Lim, Lee-Ling, Lindholm, Daniel , Liu, Haipeng , Liu, Xianliang, Liu, Xuefeng, Liu, Yubo, Livingstone, Katherine M., Llanaj, Erand , Lokunarangoda, Niroshan Chandrajith, López-Gil, José Francisco, Lui, Pauline Po Yee, Luo, Peng, Lv, Lei, Lytvyak, Ellina, Ma, Kevin Sheng-Kai, Mabrok, Mahmoud, Machoy-Rakoczy, Monika , Madinehzad, Seyed Ataollah , Maffia, Pasquale, Gomez, Javier A. Magaña, Mahmood, Nozad Hussein, Malik, Md. Zubbair, Malta, Deborah Carvalho, MAMAND, DOSTE RASHID, Maniya, Muhammad Talha, Mansoor, Farheen, Mansourian, Marjan, Manzoor, Shaista, Marghani, Basma Hamed, Martinez-Piedra, Ramon, Martini, Santi, Martorell, Miquel, März, Winfried, Marzouk, Sammer, Masi, Stefano, Masrouri, Soroush , Maude, Richard J. , Mavrovounis, Georgios, McPhail, Steven M., Mendoza, Walter, Menezes, Ritesh G., Mengistie, Emiru Ayalew, Menon, Tara P., Mestrovic, Tomislav, Mettananda, Chamila Dinushi Kukulege, Metwally, Mohamed M.M., Jonasson, Junmei Miao , Mikrajab, Muhammad Agus Naufal, Minhas, Abdul Mannan Khan, Mirrakhimov, Erkin M., Mitra, Sayan , Mitra, Tridip, Modi, Dhruti, Mohamed, Mona Gamal, Ahmed, Khabab Abbasher Hussien Mohamed, Mohammad, Ameen Mosa , Mohammadi, Saeed, Mohammed, Omer, Mohan, Syam , Molla, Tewodros Shibabaw, Molokhia, Mariam, Moni, Mohammad Ali, Namin, Sara Montazeri , Morovvati, Mahdis, Heris, Reza Mosaddeghi, Motappa, Rohith, Mousavi, Seyed Ahmad , Kiasary, Seyed Mohamad Sadegh Mousavi, Yousefi, Kimia Mozahheb , Mubarik, Sumaira, Munkhsaikhan, Yanjinlkham, Musa, Sani, Mwita, Julius C., Nabipoorashrafi, SeyedAli, Nagarajan, Ahamarshan Jayaraman , Naik, Ganesh R., Naik, Hiten, Nainu, Firzan, Nartey, Yvonne , Nassar, Mahmoud, Natto, Zuhair S., Naureen, Zakira, Nawaiseh, Hala Khaled, Nayak, Biswa Prakash, Nayak, Vinod C., Nazari, Mojdeh, Ndakotsu, Andrew , Nega, Amanuel Tebabal , Nega, Mulata H., Negash, Abigia Ashenafi, Negoi, Ionut, Nguyễn, Cao Duy, Nguyen, Cuong Tat , Nguyen, Hau Thi Hien, Nguyen, Nghia Phu , Nguyen, Phat Tuan , Nguyen, Van Thanh, Niazi, Robina Khan, Nomura, Shuhei , Noreen, Mamoona , Nawsherwan, Noubiap, Jean Jacques, Nugen, Fred, Nur, Aqsha, Odediji, Saheed Adeyinka, Ogunmodede, O.S., Ojedoyin, Olusegun Olatunji , Ojo, Oluwafemi Adeleke , Okati-Aliabad, Hassan, Oliveira, Gláucia Maria Moraes, Olorukooba, Abdulhakeem Abayomi, Ong, Qi Chwen, Orru, H, Ortiz, A., Ortiz-Prado, Esteban, Osborne, Augustus, Osei, George Nkrumah , Ostrominski, John W. , Oumer, Abdu, Ouyahia, Amel, Owolabi, Mayowa O., Oyebola, Kolapo, Ozsahin, Ilker, Anand, Mahesh Padukudru, Palicz, Tamás , Panda, Sujogya Kumar , Pandi-Perumal, Seithikurippu R., Panos, Georgios D., Papadimopoulos, Ilias, Parija, Pragyan Paramita , Parikh, Romil R., Pascucci, Eleonora, Pasovic, Maja , Passera, Roberto, Patel, Mitesh, Patel, Niki Rut, Patel, Satyananda, Patil, Ashlesh, Patil, Shankargouda, Patoulias, Dimitrios, Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarcikova, Jarmila, Peprah, Prince, Pereira, Gavin, Pirera, Edoardo , Plotnikov, Evgenii, Poluru, Ramesh, Prasad, Manya, Prashant, Akila, Prates, Elton Junio Sady, Pugliese, Nicola Riccardo, Puvvula, Jagadeesh, Qi, Xiang, Qureshi, Ali, Radhakrishnan, Venkatraman, Raghav, Pankaja, Raghav, Yashpal Singh Raghav, Raghuveer, Pracheth , Rahim, Fakher , Rahim, Hawbash Mohammed-Amin, Rahimi, Sajjad, Rahman, Fryad Majeed, Rahman, M Sajjadur , Rahman, Mohammad Hifz Ur, Rahman, Mosiur, Rajendran, Judah, Rajput, Prashant, Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rao, Asad Gul , Rao, Mithun , Rao, Sowmya J, Rasouli-Saravani, Ashkan, Rath, Shree, Rathi, Isha, Rawaf, David Laith , Rawaf, Salman, Reddy, Murali Mohan Rama Krishna, Rezaei, Mina, Rezaei, Nazila, Rezaeian, Mohsen , Rodriguez, Jefferson Antonio Buendia, Roever, Leonardo, Ross, Allen Guy Patrick, Rubeshkumar, Polani, Rwegerera, Godfrey Mutashambara , Saad, Aly M. A., Sabet, Cameron John, Sadarangani, Kabir P., Rafiei, Seyed Kiarash Sadat, Sadeghi, Ehsan, Sadeghi, Erfan, Sadeghi, Masoumeh, Sadek, Bassem, Sadek, Mustafa, Sadr, Hossein, Saeb, Mohammad Reza, Saeed, Umar, Saeedi, Maryam , Safiullah, Muhammad , Sahebkar, Amirhossein, Sajadi, S Mohammad, Saleh, Mohamed A., Salehi, Mahdi , Salimi, Sohrab, Samargandy, Saad, Samy, Abdallah M., Saravanan, Aswini , Sarfo, Jacob Owusu, Sarode, Gargi Sachin, Sarode, Sachin C., Sathian, Brijesh, Far, Mehrdad Savabi, Schlaich, Markus P., Schuermans, Art, Sejben, Anita, Semreen, Mohammad H., Senol, Yigit Can, Sessa, Francesco, Sewor, Christian , Seylani, Allen, Shahrahmani, Fatemeh, Shahwan, Moyad Jamal, Sham, Sunder, Shan, Dan, Sharifan, Amin , Sharma, Kamal, Sharma, Ravi Kumar, Sharma, Ujjawal , Shehzadi, Somia , Shetty, Mahabalesh, Shetty, Pavanchand H, Shi, Fanchao , Shi, Huizhong , Shi, Yongfeng, Shiri, Rahman , Shittu, Aminu, Shiue, Ivy, Shoaib, Ambreen, Shool, Sina, Shorofi, Seyed Afshin, Shuval, Kerem, Sia, Ching-Hui, Silva, Luís Manuel Lopes Rodrigues, Singh, Amit, Singh, Baljinder, Singh, Harmanjit, Singh, Harpreet, Singh, Lucky, Singh, Paramdeep, Singh, Siddharth , Singh, Sunil Kumar, Singh, Surjit, Singh, Vanshika , Sinha, Mukesh Kumar, Skryabin, Valentin Yurievich, Sokhal, Balamrit Singh , Sood, Prashant , Soraneh, Soroush , Sorensen, Reed J D , Srivastav, Prateek , Stanikzai, Muhammad Haroon , Starodubova, Antonina V., Stubbs, Peter, Suhag, Alisha, Sulaiman, Sahabi K., Odidi, Muritala Suleiman, Sulistiyorini, Desy , Sun, Jing , Sun, Zhong, Szarpak, Lukasz, Ty, Sree Sudha, Damavandi, Payam Tabaee, Tabatabaei, Seyyed Mohammad, Tabatabai, Shima, Tagiisuran, Balamurugan, Ali, Eman Taha Osman, Soodejani, Moslem Taheri, Taiba, Jabeen, Tajabadi, Shima, Talic, Stella, Talukder, Ashis, Adugna, Dessalegn Tamiru, Tampa, Mircea, Tan, Jianye, Tanabayeva, Dariga, Tanashat, Mohammad , Tang, Jiahao , Tantisattamo, Ekamol, Tariq, Saba, Temsah, Reem, Teramoto, Masayuki, Tesfamariam, Wegen Beyene , Tewari, Jay , Thakar, Vidhi, Thangavelu, Lakshmi, Tharwat, Ismaeel, Thiruvengadam, Muthu , Thomas, Nikhil Kenny, Ticoalu, Jansje Henny Vera, Tiwari, Krishna, Tleshev, Madi, Tonelli, Marcello, Topór-Mądry, Roman , Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Tran, An Thien, Tran, Thang Huu, Duc, Nguyen Tran Minh , Tricò, Domenico , Tse, Gary, Tseriotis, Vasilis-Spyridon, Tualeka, Abdul Rohim , Tye, Sok Cin , Ullah, Riaz, Umair, Muhammad, Umar, Lawan , Ozsahin, Dilber Uzun, Uzunçıbuk, Hande, Vaithinathan, Asokan Govindaraj , Vakili, Omid , Eynde, Jef Van den, Varghese, Joe, Vellingiri, Balachandar, Verma, Poonam, Villalobos-Daniel, Victor E., Vlassov, Vasily, Wang, Nelson, Wang, Qingzhi, Wang, Wanzhou, Wang, Wei, Wang, Yanzhong, Wang, Zhihua, Wani, Tanveer A.A., Wei, Melissa Y., Weintraub, Robert G., Wibowo, Yohanes Cakrapradipta, Wickramasinghe, Dakshitha Praneeth, Wickramasinghe, Nuwan Darshana, Witts, William Kwame , Wonde, Tewodros Eshete , Wongsin, Utoomporn , Wu, Peng, Xiao, Guangqin, Xie, Wanqing , Xu, Suowen, Xu, Wanqing, Yadav, Vikas , Yahoo, Saba, Yang, Hanwen, Yano, Yuichiro , Yao, Haiqiang , Yarahmadi, Amir, Yin, Dehui , Yismaw, Yazachew Engida, Yon, Dong Keon, Yu, Chuanhua, Yu, Elaine A., Yu, Hairui , Yu, Yong , Yuan, Quan, Zafar, Mubashir , Zaghampour, Manijeh, Zamora, Nelson, Zanghì, Aurora , Zargar, Seema , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Beijian, Zhang, Hanyu, Zhang, Julio Min Fei, Zhang, Yunquan, Zhang, Zhichang, Zhanuzakov, Murat , Zhao, Zhongyi, Zheng, Ming‐Hua , Zhong, Anthony , Zhong, Claire Chenwen, Zhou, Hao, Zhou, Jiayan, Zhou, Xiao-Dong, Zhu, Zhengyang , Zhumagaliuly, Abzal, Zitoun, Osama A. , Zoghi, Ghazal , Zoromba, Mohamed Ali, Zumla, Alimuddin, Zyoud, Sa’ed H., Hay, Simon I., Mokdad, Ali H., Murray, Christopher J. L., Roth, Gregory A., Sun, Zhong , Hay, Simon I , Roever, Leonardo , Krishan, Kewal , Moni, Mohammad Ali , Buendía, Jefferson Antonio , Badar, Muhammad , Wickramasinghe, Nuwan Darshana , Nassar, Mahmoud , Dewan, Syed Masudur Rahman , Naik, Ganesh R. , Wang, Yanzhong , Rath, Shree , Karakasis, Paschalis , Zheng, Ming-Hua , Taiba, Jabeen , Razo, Christian , DeCleene, Nicole K., LeGrand, Kate E , Abaraogu, Ukachukwu Okoroafor , ElHafeez, Samar Abd , Abdelmasseh, Michael , Abdelnabi, Mahmoud , Abd‐Elsalam, Sherief , Elshenawy, Rasha Abdelsalam , Abdelwahab, Siddig İbrahim , Abdolizadeh, Ali , Abdollahi, Arash, Abdoun, Meriem , Abdrabou, Mostafa M. , Abdulah, Deldar Morad , Abdullahi, Auwal , Shenkut, Melese, Abiodun, Olugbenga Olusola , Abiodun, Olumide A , Abohashem, Shady , Abtahi, Dariush , Farha, Rana Kamal Abu , Abubakar, Bilyaminu , Abuhelwa, Ahmad Y. , Abukhadijah, Hana J , Aburuz, Salahdein , Adamu, Nuhu Lawan , Adane, Mesafint Molla , Addo, Isaac Yeboah , Adedokun, Kamoru Ademola , Adekola, Saheed Ayodeji, Adesina, Miracle Ayomikun , Adisu, Molalign Aligaz , Adnan, Mohd , Afoakwah, Clifford , Afolabi, Aanuoluwapo Adeyimika, Afrifa‐Yamoah, Ebenezer , Afzal, Saira , Agordoh, Percival Delali , Ahmad, Aqeel , Ahmad, Khabir , Ahmad, Sajjad , Ahmed, Gasha Salih, Ahmed, Nesredin , Ajami, Marjan , Akhtar, Muhammad Nadeem , Akindele, Mukadas Oyeniran , Akkaif, Mohammed Ahmed , Akyea, Ralph Kwame , Zoubi, Mohammad Ahmmad Mahmoud Al, Alalwan, Tariq A. , Al‐Aly, Ziyad , Al-Amri, Issa Sulaiman , Alanzi, Turki Matar Khalaf, Al-Ashwal, Fahmi Y. , Al‐Azayzih, Ahmad , Al-Azzam, Sayer , Al-Bashaireh, Ahmad M. , ALBashtawy, Mohammed , Aleidi, Shereen M. , Algahtani, Fahad D. , AlHabib, Khalid F. , Ali, Abid , Ali, Asgar , Ali, Bassam R. , Al‐Iede, Montaha , Alif, Sheikh Mohammad , Alipour, Morteza, Al‐Jabi, Samah W. , Aljunid, Syed Mohamed , Alkubati, Sameer Abdulmalik , Almagharbeh, Wesam Taher , Almahmeed, Wael , Almazan, Joseph Uy , Alniss, Hasan Yaser , Alomari, Mahmoud A. , Alotaibi, Haifa F. , Alqahtani, Saleh A. , Alqudimat, Mohammad R. , Al-Qudimat, Ahmad Rajeh , Al‐Raddadi, Rajaa , Alsbou, Mohammed , Alshahrani, Najim Zafer , Al-Shami, Ali Salman , Altaf, Awais , Althobiani, Malik A , Alwafi, Hassan , Al‐Worafi, Yaser Mohammed , Aly, Hany Z. , Al‐Zalabani, Abdulmohsen H. , Alzoubi, Abdallah , Alzoubi, Karem Hasan , Amafah, Joy, Amin, Amr , Amini, Saeed, Amini‐Salehi, Ehsan , Amusa, Ganiyu , Ang, Song Peng , Anieto, Ebuka Miracle , Anil, Abhishek , Anjana, Dr. Prapti, Anvari, Saeid, Appati, Walter , Arabloo, Jalal , Arafat, Mosab , Areda, Demelash, Arefnezhad, Reza , Torre, Jorge Arias de la, Aripov, Timur , Arockiaraj, Jesu , Asdaq, Syed Mohammed Basheeruddin , Ashraf, Syed Amir , Ashraf, Tahira , Ataç, Ömer , Athar, Mohammad , Athari, Seyyed Shamsadin , Aurangzeb, Khursheed , Awan, Sana Javaid , Awol, Kemal Lemnuro, Awotidebe, Adedapo Wasiu , Aylı, Berrak Itır , Azarboo, Alireza , Aziz, Sadat Abdulla , Azzolino, Domenico , Babu, Abraham Samuel , Babu, Giridhara R. , Badiye, Ashish , Baghlaf, Khlood K , Baig, Atif Amin , Bakhshali, Mohamad Amin , Banach, Maciej , Banik, Palash Chandra , Barqawi, Hiba Jawdat , Barrow, Amadou , Barua, Lingkan , Bashir, Shahid , Bashiri, Azadeh , Bastan, Mohammad‐Mahdi , Bayih, Mulat Tirfie , Beeraka, Narasimha Murthy , Begum, Tahmina , Behera, Priyamadhaba , Behnam, Babak , Ramírez, Diana Fernanda Bejarano , Belo, Luı́s , Berihun, Abiye Assefa , Bhattacharjee, Priyadarshini , Bhatti, Gurjit Kaur , Bhatti, Jasvinder Singh , Biswas, Atanu , Biswas, Bijit , Bizzozero‐Peroni, Bruno , Bodur, Mahmut , Bogale, Sitotaw Kerie , Bohn, Lucimére , Boloor, Archith , Carvajal, Alejandro Botero , Boudalia, Sofiane , Bugiardini, Raffaele , Busch, Felix , Bustanji, Yasser, Campos, Luciana Aparecida , Catapano, Alberico Luigi , Cegolon, Luca , Cenko, Edina , Cerin, Ester , Chakraborty, Chiranjib , Chandika, Rama Mohan , Chandrasekar, Eeshwar K , Chandrasekaran, Baskaran , Chattu, Vijay Kumar , Chaudhary, Anis Ahmad , Chaudhuri, Sirshendu , Cheema, Asad Ali Ahmed , Chichagi, Fatemeh , Ching, Patrick R , Cho, William C.S., Choi, Dong‐Woo , Chong, Bryan , Chopra, Deepti , Chopra, Hitesh , Choudhari, Sonali Gajanan , Chu, Dinh‐Toi , Chukwu, Chidozie Williams , Chung, Sheng‐Chia , Chung, S. Y. , Cicero, Arrigo F.G. , Cosma, Claudia , Criqui, Michael H. , Dadras, Omid , Dai, Xiaochen , Dai, Zhaoli , Dalakoti, Mayank , D’Amico, Emanuele , Tesfa, Endalamaw , Danpanichkul, Pojsakorn , Darcho, Samuel Demissie , Davletov, Dimash , Davletov, Kairat , Dejenie, Tadesse Asmamaw , Bo’, Cristian Del , Delgado‐Enciso, Iván , Denova‐Gutiérrez, Edgar , Dergaa, Ismail , Dervišević, Emina , Devegowda, Devananda , Dewan, Syed Masudur Rahman , Dhimal, Meghnath , Dhungel, Bibha , Do, Thanh Chi, Phuong, Thao Huynh, Doshi, Ojas Prakashbhai , Doshi, Rajkumar , Dourado, Paulo Magno Martins , Dowou, Robert Kokou , Du, Mi , Duncan, Bruce Bartholow , Durães, André Rodrigues , Ebohon, Osamudiamen , Eftekhari, Behrad , Eladl, Mohamed Ahmed , Eldaboush, Ahmed , Elgendy, Islam Y. , Elhadi, Muhammed , El‐Huneidi, Waseem , Elmonem, Mohamed A. , Elmoselhi, Adel B. , Fabin, Natalia , Fadaka, Adewale Oluwaseun , Fagbamigbe, Adeniyi Francis , Fakorede, Sodiq , Fatima, Zareen , Fayaz, Mohammad , Fazylov, Timur, Fernández‐Jiménez, Rodrigo , Fischer, Florian, Fogacci, Federica , Foschi, Matteo , Gadanya, Muktar A., Gajdács, Márió , Galali, Yaseen , Ganesan, Balasankar , Gangachannaiah, Shivaprakash , Gašević, Danijela , Habtemichael, Mizan , Getacher, Lemma , Jolfayi, Amir Ghaffari , Ghamkhar, Arin, Ghazy, Ramy Mohamed , Ghimire, Sailaja, Ghith, Nermin , Gil, Artyom , Gill, Paramjit Singh , Gnedovskaya, Elena V. , Goh, Lay Hoon , Gohari, Kimiya, Golechha, Mahaveer , Goulart, Alessandra C. , Goyal, Aman , Grada, Ayman , Gu, Long , Gubari, Mohammed Ibrahim Mohialdeen , Guha, Avirup , Gunawardane, Damitha Asanga , Gupta, Rajeev , Gurgoglione, Filippo Luca , Guzmán-Esquivel, José , Guzmán-Muñoz, Eduardo , Haghtalab, Arian , Halder, Pritam , Hamdy, Nadia Μ. , Hammad, Eman A. , Hanif, Asif , Hanifi, Nasrin , Hankey, Graeme J. , Harsini, Sara , Hartmann, Phillipp , Hasan, Ikramul , Hashempur, Mohammad Hashem , Hassan, Amr , Hassan, Ibrahim Nagmeldin , Hayat, Khezar , Hezam, Kamal , Hiraike, Yuta , Holla, Ramesh , Hostiuc, Sorin , Htay, Mila Nu Nu , Huang, Junjie, Hushmandi, Kiavash , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ibrahim, Khalid S. , Ibrayeva, Anel , Ikram, Jibran, Ilesanmi, Olayinka Stephen , Ilić, Irena , Ilić, Milena , Imodoye, Sikiru O. , Inbaraj, Leeberk Raja , Ionescu, Radu Tudor, Iqhrammullah, Muhammad , Irham, Lalu Muhammad , Ishaqui, Azfar Athar , Ismail, Nahlah Elkudssiah , Ismoldayev, Yerlan, Isola, Gaetano , Izquierdo‐Condoy, Juan S. , Jacob, Jaison , Jahanshahi, Ali , Jamal, Armaan , Jamali, Navid , James, Jerin , Jamshidi, Masoud , Jawaid, Talha, Jayasinghe, Yovanthi Anurangi , Jemal, Mohammed , Jeong, Seogsong , Jeswani, Bijay Mukesh , Jibat, Nathan Tolemariam , Jokar, Mohammad , Joó, Tamás , Joseph, Akaninyene Paul , Joseph, Mickaël Antoine , Joseph, Nitin , Joshi, Krupal , Jürisson, Mikk , K, Vaishali , Kakkar, Ashish Kumar , Kalani, Rizwan , Kalavani, Khalil , Kalra, Sanjay , Kamorudeen, Ramat T. , Kamyshnyi, Oleksandr , Kanaan, Saddam Fuad , Kanmodi, Kehinde Kazeem , Kantar, Rami S. , Kapoor, Neeti , Karajizadeh, Mehrdad , Karakasis, Paschalis , Karasneh, Reema A. , Kashoo, Faizan , Kashyap, Manoj Kumar , Kausar, Mohd Adnan , Kazemian, Sina , Kebede, Yabets Tesfaye , Kesse‐Guyot, Emmanuelle , Khademi, Reza , Khader, Yousef , Khajuria, Himanshu , Khaleel, Anas , Khalid, Sidra , Khalili, Anita , Khalili, Pantea , Khan, Maseer , Khan, Mohammad Idreesh , Khasbage, Sameer Uttamaro , Khatatbeh, Moawiah Mohammad , Khosla, Pavan , Khosravi, Sepehr , Kimokoti, Ruth W , Kısa, Adnan , Kishore, Ladli , Kivimäki, Mika , Kokkorakis, Michail , Kolahi, Ali‐Asghar , Kompani, Farzad , Kondybayeva, Аida , Korzh, Oleksii , Kostev, Karel , Laxminarayana, Sindhura Lakshmi Koulmane , Kua, Chong-Han , Kuddus, Mohammed , Kumar, Chandan , Kumar, G Anil , Kumar, Jogender , Kumar, Laksh , Kundu, Amartya , Kundu, Satyajit , Kunutsor, Setor K. , Kurniasari, Maria Dyah , Kytö, Ville , Lahariya, Chandrakant , Lakanova, Balzhan, Lantos, Tamás , Larebo, Yilma Markos , Lasrado, Savita , Lee�, HwaMin , Lee, Wei‐Chen , Leivaditis, Vasileios , Lenjisa, Jimma Likisa , Li, Ming‐Chieh , Li, Qiang , Li, Shaojie , Lim, Lee-Ling , Lodhi, Madeeha Shahzad , Lokunarangoda, Niroshan Chandrajith , López-Gil, José Francisco , Lorkowski, Stefan , Lucchetti, Giancarlo , Lui, Pauline Po Yee , Lv, Lei , Lytvyak, Ellina , Amin, Hawraz Ibrahim M. , Maffia, Pasquale , Magaña‐Gómez, Javier A. , Mahalleh, Mehrdad , Malik, Ahmad Azam , Malik, Tabarak , Malta, Déborah Carvalho , Mamand, Doste R. , Maniya, Muhammad Talha , Mannethodi, Kamaruddeen , Mansoor, Farheen, Mansourian, Marjan , Maqsood, Kaleem , Marateb, Hamid Reza , Marghani, Basma H. , Marino, Mirko , Martínez, Ramón , Martini, Daniela , Martini, Santi , Martorell, Miquel , März, Winfried , Marzouk, Sammer , Masi, Stefano , Mathur, Neeta , Matozinhos, Fernanda Penido , Mattiello, Rita , Mavrovounis, Georgios , McPhail, Steven , Mehto, Subhash , Meles, Hadush Negash , Menezes, Godfred Antony , Menon, Tara Pattilachan, Mensah, George A. , Merlino, Giovanni , Meštrović, Tomislav , Mettananda, Chamila Dinushi Kukulege , Mettananda, Sachith , Metwally, Mohamed M M, Mikrajab, Muhammad Agus, Minhas, Abdul Mannan Khan , Mittal, Madhukar , Mohamed, Nouh Saad , Ahmed, Khabab Abbasher Hussien Mohamed , Mohammad, Taj , Mohammadi, Abbas , Mohammadi, Mokhtar , Mohammadian-Hafshejani, Abdollah , Mohsen, Yazan , Shibabaw, Tewodros , Molokhia, Mariam , Monazzami, Amirabbas , Ghalibaf, AmirAli Moodi , Morovvati, Mahdis, Motappa, Rohith , Mozafar, Mehrdad , Mubarik, Sumaira , Muhammad, Jibran Sualeh , Munkhsaikhan, Yanjinlkham, Munshi, Anjana , Musa, Sani , Muthu, Sathish , Mwita, Julius Chacha , Myung, Woojae , Nainu, Firzan , Nargus, Shumaila , Nasrollahizadeh, Amir , Nassar, Mahmoud, Nauman, Javaid , Navaratna, Samidi Nirasha Kumari , Nawaiseh, Hala K. , Nayak, Biswa Prakash, Nega, Mulata Haile , Negash, Abigia Ashenafi , Negoi, Ionuţ , Abadi, Reza Nejad Shahrokh , Nematollahi, Mohammad Hadi , Nieddu, Luciano , Nketia, Richmond , Noubiap, Jean Jacques , Nri-Ezedi, Chisom Adaobi , Ntsekhe, Mpiko , Nugen, Fred , Oancea, Bogdan , Odat, Ramez M. , Oddi, Fabio Massimo , Oh, In‐Hwan , Okekunle, Akinkunmi Paul , Okonji, Osaretin Christabel , Olorukooba, Abdulhakeem Abayomi , Ong, Qi Chwen , Ordak, Michał , Orscelik, Atakan , Ortiz‐Prado, Esteban , Osuagwu, Uchechukwu Levi , Oumer, Abdu , Ouyahia, Amel , Özşahin, İlker , Padrón‐Monedero, Alicia , Padubidri, Jagadish Rao , Panos, Georgios D. , Papa, Mario Virgilio , Pardhan, Shahina , Passera, Roberto , Patel, Kunal Nitinkumar , Patel, Neel Navinkumar , Patel, Satyananda, Patil, Shankargouda, Patoulias, Dimitrios , Pattnaik, Snigdha, Toroudi, Hamidreza Pazoki, Pekarčíková, Jarmila , Peprah, Prince , Pereira, Gavin, Perico, Norberto , Perna, Simone , Petermann‐Rocha, Fanny , Pirnejad, Habibollah , Plotnikov, Evgenii, Poddighe, Dimitri , Poluru, Ramesh , Porntaveetus, Thantrira , Pradhan, Pranil Man Singh , Prasad, Manya , Prashant, Akila , Pugliese, Nicola Riccardo , Puvvula, Jagadeesh , Qiu, Jia-Yong , Radhakrishnan, Venkatraman, Raghav, Pankaja Raghav, Rahamon, Sheu Kadiri , Rahim, Hawbash Mohammed-Amin , Rahimi, Sajjad , Rahman, Muhammad Aziz , Raj, Jeffrey Pradeep , Raja, Adarsh , Rajendran, Judah , Rajput, Prashant , Ramadan, Mahmoud M. , Ramasamy, Chitra, Ramasamy, Shakthi Kumaran, Rashedi, Vahid , Rasouli‐Saravani, Ashkan , Rath, Shree , Rathi, Isha , Rathish, Devarajan , Rauniyar, Santosh Kumar , Rawassizadeh, Reza , Ray, Asit , Redwan, Elrashdy M , Rehman, Najeeb Ur , Remuzzi, Giuseppe , Rezaei, Nazila , Romadlon, Debby Syahru , Romoli, Michele , Rony, Moustaq Karim Khan , Ross, Allen Guy , Roy, Sharmistha , Roy, Shubhanjali , Russo, Michele , Saber-Ayad, Maha Mohamed , Sabet, Cameron John , Sadarangani, Kabir P. , Rafiei, Seyed Kiarash Sadat , Saddique, Muhammad Nabeel , Sadee, Bashdar Abuzed , Sadeghi, Masoumeh , Sadek, Bassem Shaban , Sadr, Hossein, Saeb, Mohammad Reza , Saeed, Mοhd , Saeedi, Maryam , Saghazadeh, Amene , Sagoe, Dominic , Sah, Ashok Kumar , Sharif‐Askari, Fatemeh Saheb , Sahebkar, Amirhossein , Sajadi, S. Mohammad, Sajid, Mirza Rizwan , Saki, Morteza , Sakshaug, Joseph W. , Salami, Afeez Abolarinwa , Saleem, Rahman Shah Zaib , Salihu, Abubakar Tijjani , Salimi, Sohrab , Samargandy, Saad J. , Samodra, Yoseph Leonardo , Samy, Abdallah M., Sarfo, Jacob Owusu , Sarmadi, Mohammad , Sarode, Gargi Sachin , Sassano, Michele , Sathian, Brijesh , Narayanan, Mukesh Kumar Sathya , Schlaich, Markus P. , Schuermans, Art , Schwarz, Ghil , Sejben, Anita , Selvaraj, Siddharthan , Semreen, Mohammad H. , Şenol, Yiğit Can , Şerban, Dragoş , Sethi, Yashendra , Setiawan, Christianus Heru , Shahid, Samiah , Shahini, Endrit , Shahrahmani, Fatemeh, Shahwan, Moyad Jamal , Shamim, Muhammad Aaqib , Shamsi, Anas , Shan, Dan, Shanawaz, Mohd , Shannawaz, Mohammed , Sharif, Nadim , Sharma, Bhoopesh Kumar , Sharma, Bunty, Sharma, Manoj , Sharma, Vishal , Shastry, Shamee , Sheidaei, Ali , Shenoy, Rekha R. , Shimels, Tariku , Shittu, Aminu , Shoaib, Ambreen , Shool, Sina , Shrestha, Sunil , Shuval, Kerem , Sia, Ching‐Hui , Siddig, Emmanuel Edwar , Siddiqi, Ahmed Kamal , Siddiqua, Ayesha , Silva, Diego Augusto Santos , Simkhada, Padam Prasad , Singh, Amit Kumar, Singh, Baljinder, Singh, Harpreet, Singh, Jasvinder A. , Singh, Lucky, Singh, Poornima Suryanath , Singh, Puneetpal , Sinha, Mukesh Kumar , Sinha, Ratnesh , Skryabin, Valentin Yurievich , Sorrentino, Michele , Spartalis, Michael , Stachteas, Panagiotis , Владимировна, Стародубова Антонина, Straube, Sebastian , Stubbs, Peter W. , Su, Chen‐Yang , Subramaniyan, Vetriselvan , Suhag, Alisha , Sulaieva, Oksana , Sun, Jing , Swain, Chandan Kumar , Szarpak, Łukasz , Y, Sree Sudha T, Damavandi, Payam Tabaee , Tabarés‐Seisdedos, Rafael , Tabatabaeizadeh, Seyed‐Amir , Tabche, Celine , Tadele, Afework , Ali, Eman T. , Soodejani, Moslem Taheri , Tajabadi, Shima, Talic, Stella , Talukder, Ashis , Zadeh, Seyed Saeed Tamehri , Tampa, Mircea Ştefan , Tantisattamo, Ekamol , Tariku, Mengistie Kassahun , Tavangar, Seyed Mohammad , Tedla, Mebrahtu G. , Teramoto, Masayuki , Tesfu, Azimeraw Arega , Tharwat, Ismaeel, Tharwat, Samar , Thienemann, Friedrich , Tiruye, Tenaw Yimer , Tleshev, Madi, Tomo, Sojit , Tonelli, Marcello , Touvier, Mathilde , Tran, An Thien, Tran, Thang Huu, Tristan, Christopher Daniel , Tse, Gary , Tseriotis, Vasilis‐Spyridon , Udoakang, Aniefiok John , Ullah, Atta , Ullah, Saeed , Umair, Muhammad, Upadhya, Dinesh , Upadhyay, Era , Usman, Jibrin Sammani , Ozsahin, Dilber Uzun , Uzunçıbuk, Hande , Varghese, Joe , Vasankari, Tommi Juhani , Vellingiri, Balachandar , Venketasubramanian, Narayanaswamy , Verma, Akshaya Kumar , Villalobos-Daniel, Victor Eduardo , Wan, Jin‐Yi , Wang, Cong , Wang, Nelson , Wang, Shaopan , Wang, Shu , Wang, Youxin , Wani, Tanveer A. , Waqar, Ahmed Bilal , Weintraub, Robert G, Wibowo, Yohanes Cakrapradipta, Wicaksana, Anggi Lukman , Wickramasinghe, Dakshitha Praneeth , Wilandika, Angga , Xu, Site , Xu, Suowen , Xu, Xiaoyue , Yadegar, Amirhossein , Yahoo, Saba, Yamagishi, Kazumasa , Yaribeygi, Habib , Yesuf, Subah Abderehim , Yon, Dong Keon , Yonemoto, Naohiro , Yuan, Quan, Yuzbashian, Emad , Zamagni, Giulia , Zawiah, Mohammed , Zeariya, Mohammed G M, Zeru, Eyael M, Zhang, Casper J. P. , Zhong, Claire Chenwen , Zhou, Xiao-Dong, Zhumagaliuly, Abzal , Zoromba, Mohamed Ali , Zumla, Alimuddin I. , Zyoud, Ahed H. , Zyoud, Shaher H. , Mokdad, Ali H. , Murray, Christopher J. L., Roth, Gregory A., Kheirallah, Khalid Ahmed , Saad, Aly M A , Sadeghi, Erfan

Mayo Clinic

JAMA | July 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.8628 | PMID 42525403 Get It

Importance Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C–related burden is critical for guiding prevention and treatment strategies. Objectives To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends. Design, Setting, and Population This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals. Exposure Population-level LDL-C concentrations. Main Outcomes and Measures Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C–attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals. Results In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C–attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings. Conclusions and Relevance Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004
Wierda, William G. , Dorritie, Kathleen , Gauthier, Jordan , Nath, Rajneesh, Kipps, Thomas J. , Riedell, Peter A. , Eradat, Herbert A., Kharfan‐Dabaja, Mohamed A. , Shah, Nirav N. , Solomon, Scott R., Stephens, Deborah M., Ermann, Daniel A., Arnason, Jon , Deol, Abhinav , Feldman, Tatyana , Ghosh, Monalisa , Tuazon, Sherilyn A., Perna, Serena K., Ou, San-San, Ananthakrishnan, Revathi , Rane, Neha, Papp, Eniko, Ansari, Sahar , Thompson, Ethan G., Okal, Abood, Peiser, Leanne, Chen, Yizhe , Sengupta, Sanhita , Wang, Jixian , Wierda, William G. , Dorritie, Kathleen , Kenderian, Saad S. , Kharfan-Dabaja, Mohamed A , Shah, Nirav N , Deol, Abhinav , Ma, Shuo , Schuster, Stephen J , Gergis, Usama , Vose, Julie , Soumerai, Jacob D , Besien, Koen van , Chen, Yizhe , Sengupta, Sanhita , Ray, Pradipta Ranjan , Siddiqi, Tanya , Kipps, Thomas J , Riedell, Peter A , Nath, Rajneesh , Eradat, Herbert, Stephens, Deborah M. , Andreadis, Charalambos Babis , Ma, Shuo , Schuster, Stephen J. , Vose, Julie M. , Soumerai, Jacob D. , Tuazon, Sherilyn A. , Perna, Serena , Ou, San‐San , Papp, Eniko , Ansari, Sahar, Siddiqi, Tanya

Mayo Clinic

Blood Journal | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026033565 | PMID 42520199 Get It

Patients in the liso-cel plus ibrutinib cohort of the phase 1/2, open-label TRANSCEND CLL 004 study had relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and received liso-cel (50×106 [dose level (DL)1] or 100×106 [DL2] chimeric antigen receptor-positive T cells) with concurrent ibrutinib from enrollment through 90 days after liso-cel infusion or longer per investigator discretion. Primary end point was complete response/remission (CR)/CR with incomplete marrow recovery (CRi) by investigator assessment. Among 56 patients who received ibrutinib plus liso-cel (DL1, n=5; DL2, n=51), median (range) age was 64.5 years (44‒77), 98% had high-risk cytogenetics, 55% had progression on Bruton tyrosine kinase inhibitor and venetoclax failure, and median (range) number of prior therapies was 5 (1‒13). Median (range) follow-up was 24.8 months (3.1‒51.8). At DL2, CR/CRi rate was 45% (95% confidence interval [CI], 31‒60) and overall response rate was 86% (95% CI, 74‒94). Median (95% CI) duration of response was not reached (NR; 28.7‒NR) for patients with CR/CRi and 41.4 months (23.3‒NR) for all responders. Median (95% CI) progression-free survival was 31.4 months (20.1‒NR). In DL1+DL2, most common grade ≥3 treatment-emergent adverse events (TEAE) were neutropenia (52%) and anemia (41%). Cytokine release syndrome was reported in 80% of patients (grade 3, 4%; no grade 4/5), and neurological events in 41% (grade 3/4, 11%; no grade 5). Ibrutinib-related TEAEs were reported in 68% of patients (grade 3/4, 43%; no grade 5). Liso-cel plus ibrutinib demonstrated notable efficacy in patients with relapsed/refractory CLL/SLL with predictable and manageable safety. Clinicaltrials.gov: NCT03331198; NCT03435796.
Peripheral cellular transcriptional changes are associated with Alzheimer’s disease related phenotypes 2330291
Wang, Xue, Tsai, Wei, Nguyen, Thuy , Reyes, Denise, Lowe, Val, Petersen, Ronald, Kantarci, Kejal, Carrasquillo, Minerva, Nho, Kwangsik, Saykin, Andrew, Reddy, Joseph, Allen, Mariet , Ertekin-Taner, Nilüfer, Chen, Xuan , Tsai, Wei, Lowe, Val J. , Petersen, Ronald C. , Kantarci, Kejal , Carrasquillo, Minerva M. , Nho, Kwangsik T. , Saykin, Andrew J. , Reddy, Joseph S. , Ertekin‐Taner, Nilüfer

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.1795 Get It

Abstract Introduction Alzheimer’s disease (AD) is characterized by pathologies including amyloid, tau, neurodegeneration reflected in established blood biomarkers and track with clinical changes. However, the association between peripheral cell-specific signatures and AD-related phenotypes remain poorly characterized. Methods We analyzed bulk blood transcriptome data from the Mayo Clinic Study of Aging (MCSA) and Emory University Vascular study. We used BayesPrism, CIBERSORTx, and an in-house pipeline CNNreg to deconvolute these data and obtain peripheral cell proportions. Cell type specific transcripts were estimated with BayesPrism. We compared cell proportions between cases (AD/MCI) and controls. Association analysis was performed between cell type specific transcripts and AD-related phenotypes including diagnosis and cognition. Meta-analysis of transcripts associations and gene ontology analysis were conducted to assess the enriched pathways for significant genes. Results In MCSA, B and CD4+ T cells proportions are significantly lower while that of myeloid cells higher in cases. The Emory cohort had similar trends. We identified transcripts associated with AD-related phenotypes in CD4+ T and CD8+ T cells. In CD4+ T cells, transcripts downregulated in case are enriched in response to stimulus pathway, whereas those upregulated in negative regulation of immune response. Downregulation of CD4+ T genes enriched in extracellular matrix disassembly and epigenetic regulation and upregulation of those in protein localization associate with better cognition. In CD8+T cells, genes pertinent to vascular development were downregulated while those to metabolic processes were upregulated in cases. Downregulation of CD8+T genes involved in lipid transportation and upregulation of those in mitochondria associate with better cognition. Conclusion We identified peripheral cellular transcriptional changes associated with AD/MCI phenotypes and involved in important biological pathways, revealing potential disease mechanisms in AD. Funding Source RF1 AG051504 Topic Categories Neuroimmunology (NEUR)
Siglec-9 is a functional inhibitory receptor for B7-H3 that regulates anti-tumor immunity 2260091
Medlyn, Michael, Shapiro, Michael, Kimball, Brooke, Huynh, Truc, Peterson, Kevin, Crotts, Sydney, Zastrow, Alexi, Lucien, Fabrice, Kaufmann, Scott, Kenderian, Saad, Billadeau, Daniel, Shapiro, Virginia, Chen, Yin, Medlyn, Michael J. , Shapiro, Michael, Kimball, Brooke , Huynh, Truc , Crotts, Sydney B. , Zastrow, Alexi, Lucien, Fabrice , Kenderian, Saad, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.853 Get It

Abstract Introduction Checkpoint blockade revolutionized cancer therapy. However, only a small proportion of cancers respond to checkpoint blockade. B7-H3 is a member of the B7 superfamily, which includes both co-inhibitory and co-stimulatory receptors. B7-H3 is upregulated by many tumors which is generally associated with a worse prognosis. However, the exact mechanism by which B7-H3 suppresses the immune response remains elusive. Methods We transfected human HEK293T cells and assessed the binding to recombinant Siglecs via flow cytometry. We generated monoclonal antibody F7 against human B7-H3 and tested its blocking function using B7-H3 transfected HEK293T cells. We examined the extent of degranulation and NK cell-mediated killing on B7-H3 expressing HEK293T cells in vitro, as well as the CART19 cells mediated killing in relapse model of B7-H3 expressing CD19+ leukemia Nalm6 cells NSG mice. Results We demonstrated that sialylated B7-H3 binds to the inhibitory receptor Siglec-9 on immune cells but not to the related protein Siglec-7. A high affinity monoclonal antibody (mAb) F7 against B7-H3 blocks Siglec-9 binding. Functionally, F7 enhances NK cell killing of B7-H3 expressing target cells in vitro. F7 also dramatically enhances CART19 mediated killing of B7-H3 expressing Nalm6 cells in a relapse model in NSG mice in vivo. Conclusion We have now shown for the first time that B7-H3 binds to the inhibitory receptor Siglec-9 and generated a novel monoclonal antibody F7 that target a unique sequence in B7-H3 as compared to other monoclonal antibodies being examined for clinical efficacy. F7 can promote NK cell killing of B7-H3 expressing target cells in vitro and synergize with CART19 to enhance killing of B7-H3 expressing tumor cells in vivo. As B7-H3 is overexpressed in many human cancers, this work is critical toward understanding how B7-H3 mediates immune evasion through Siglec-9 for enhancing anti-tumor immunity. Funding Source R01CA243545-01A1 Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Defining the Role of HDAC3 Enzymatic vs. Adaptor Function in T Cells 2258602
Martinez, Kodi, Shapiro, Michael, Chen, Maggie, Choe, Justin, Crotts, Sydney, Maniaci, Brandon, Zastrow, Alexi, Barnes, Jackson, Carlson, Abby, Shapiro, Virginia, Martinez, Kodi, Shapiro, Michael, Crotts, Sydney B. , Zastrow, Alexi, Shapiro, Virginia Smith

Mayo Clinic

The Journal of Immunology | July 28, 2026 | Volume: 215 | Issue: Supplement_1 | Pages: No page available

10.1093/jimmun/vkag141.603 Get It

Abstract Introduction Generation of T cells requires dynamic epigenetic alteration of histones to control gene expression at each developmental stage. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) facilitate addition or removal of various acyl groups from lysine residues, including acetylation (KAc) and crotonylation (KCr). The Class I deacetylases HDAC1, HDAC2, and HDAC3 have been shown to have 3 functions: adaptor, decrotonylase, and deacetylase activity. The relative importance of each function in T cells is not known. Genetic knockout of HDAC3 in mice using CD2icre results in a severe block in T cell development and spontaneous development of severe colitis. Our lab determined that HDAC3 is required for three different aspects of this process: CD4+CD8 + (DP) cell survival, positive selection, and CD4+ lineage commitment. We generated a novel mouse model with CD2icre-mediated deletion of endogenous HDAC3 and linked re-expression of HDAC3 “VRPP” mutant mice, which maintained adaptor function but lacks enzymatic activity. Strikingly, these mice do not develop spontaneous colitis even up to one year of age. Methods We used flow cytometry to assess T cell development and maturation in the thymus, spleen, mLN, and colon of HDAC3 cKO vs. HDAC3 VRPP mice. CUT&RUN was utilized to determine differences in H3K9Ac, H3K27Ac, and H3K18Cr across CD8 and CD4 lineage genes. H&E was utilized to assess structural changes in thymus and colon. Results Similar to CD2icre HDAC3 cKO mice, HDAC3 VRPP mice have a block in positive selection due to failure to down regulate RORγt and decreased DP cell survival due to increased expression of P2RX7. Although fewer T cells are produced in HDAC3 VRPP mice, CD4+ lineage commitment is restored, likely mitigating the development of spontaneous colitis. Conclusion Our results demonstrate that HDAC3 enzymatic activity is necessary for several aspects of T cell development, while HDAC3 adaptor function is sufficient to restore CD4+ lineage commitment. Funding Source NIAID RO1 AI150100, T32 AI170478 Topic Categories Hematopoiesis and Immune System Development (HEM)